{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-006923","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.222735+00:00","generated_at":"2026-06-18T01:22:23.682867+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioLife Solutions FY2022 revenue $161.8M (+36% YoY); GAAP net loss $139.8M on $110.4M impairment","bullets":["Full year 2022 revenue $161.8M, up 36% vs 2021; biopreservation media revenue grew 45%.","GAAP net loss $139.8M (includes $110.4M non-cash impairment of Stirling Ultracold intangible assets); adjusted net loss $29.3M.","Adjusted EBITDA positive at $3.6M for full year; Q4 adjusted EBITDA $1.7M.","Reaffirms 2023 revenue guidance of $188M-$202M, 16-25% growth; cell processing platform expected $89-93M (+30-35%).","Cash and short-term investments $64.1M at year-end; Silicon Valley Bank operational with existing credit facilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-006923","json":"https://secwatch.observer/filing/0001437749-23-006923.json","markdown":"https://secwatch.observer/filing/0001437749-23-006923.md","text":"https://secwatch.observer/filing/0001437749-23-006923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/0001437749-23-006923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/bioli20230316_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:22:23.682867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e25445c48c49eef96b0205ef6499039092b27785","claim":"BIOLIFE SOLUTIONS INC reported preliminary financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 16, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/0001437749-23-006923-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}